Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc. has demonstrated a positive trajectory in its clinical development, particularly with its lead compound, epetraborole, which has shown good safety and tolerability in Phase 2 trials, with mild, reversible side effects. The candidate has elicited promising patient-reported outcomes and is anticipated to significantly improve treatment options for both MAC NTM and potentially MAB NTM, indicating a strong market position in addressing these challenging infectious diseases. The positive pre-clinical and clinical results, combined with the potential for epetraborole to fulfill an unmet medical need, bolster the company's outlook in the biopharmaceutical sector.

Bears say

AN2 Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from disappointing results from its lead candidate, epetraborole, and ongoing historical losses without a clear path to profitability. The company encounters various risks, including the likelihood of failing to meet clinical efficacy endpoints and potential litigation that could hamper market exclusivity and commercialization efforts. Additionally, competitive market conditions and internal challenges may hinder AN2's ability to successfully develop and market its pipeline candidates, further exacerbating financial vulnerabilities.

ANTX has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 6 analysts, ANTX has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.